Home
STOK
STOK News

Latest Stoke Therapeutics Inc. (STOK) News on November 17, 2024

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade

Zacks

9 days ago

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues

Simply Wall St.

11 days ago

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Zacks

12 days ago

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Business Wire

12 days ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

16 days ago

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

19 days ago

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Stoke Therapeutics assumed with an Outperform at Leerink

TipRanks

a month ago

Stoke Therapeutics assumed with an Outperform at Leerink

Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases

Insider Monkey

a month ago

Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases

MT Newswires

a month ago

Stoke Therapeutics Files Mixed Shelf

GuruFocus.com

2 months ago

Skorpios Trust Reduces Stake in Stoke Therapeutics Inc

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Business Wire

2 months ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Business Wire

2 months ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire

2 months ago

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Business Wire

2 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

3 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold

Clinical Trials Arena

3 months ago

Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Zacks

3 months ago

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Business Wire

3 months ago

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

4 months ago

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%

Simply Wall St.

4 months ago

The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

4 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

5 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth

Simply Wall St.

5 months ago

We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth

MT Newswires

5 months ago

Stoke Therapeutics Files Registration Statement For Sale of 10.8 Million Shares by Stockholders

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Business Wire

5 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

GuruFocus.com

6 months ago

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

MT Newswires

6 months ago

Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

6 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...

GuruFocus.com

6 months ago

Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...

MT Newswires

6 months ago

Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating

Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

6 months ago

Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Zacks

6 months ago

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Business Wire

6 months ago

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

MT Newswires

7 months ago

Stoke Therapeutics Appoints Thomas Leggett CFO

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Zacks

7 months ago

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Business Wire

7 months ago

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

Zacks

7 months ago

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Business Wire

7 months ago

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire

7 months ago

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Business Wire

8 months ago

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

Zacks

8 months ago

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

Stoke Therapeutics Announces Proposed Public Offering

Business Wire

8 months ago

Stoke Therapeutics Announces Proposed Public Offering

Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients

Benzinga

8 months ago

Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients

Stoke shares surge on updated results for Dravet drug

BioPharma Dive

8 months ago

Stoke shares surge on updated results for Dravet drug

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

Zacks

8 months ago

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire

8 months ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Business Wire

8 months ago

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)

Zacks

9 months ago

Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)

Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for

Zacks

9 months ago

Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

9 months ago

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

InvestorPlace

9 months ago

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Triple Threat: 3 Stocks to Buy for 3X Upside Potential

InvestorPlace

9 months ago

Triple Threat: 3 Stocks to Buy for 3X Upside Potential

Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?

Zacks

9 months ago

Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?

Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?

Zacks

9 months ago

Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?

18 Best 52-Week Low Stocks To Buy Now

Insider Monkey

10 months ago

18 Best 52-Week Low Stocks To Buy Now

A Look Back at Footwear Retailer Stocks' Q3 Earnings: Genesco (NYSE:GCO) Vs The Rest Of The Pack

StockStory

10 months ago

A Look Back at Footwear Retailer Stocks' Q3 Earnings: Genesco (NYSE:GCO) Vs The Rest Of The Pack

Gatos Silver Reports New Intercepts of High-Grade Mineralization at Cerro Los Gatos

GlobeNewswire

10 months ago

Gatos Silver Reports New Intercepts of High-Grade Mineralization at Cerro Los Gatos

Institutions profited after Innodata Inc.'s (NASDAQ:INOD) market cap rose US$76m last week but retail investors profited the most

Simply Wall St.

10 months ago

Institutions profited after Innodata Inc.'s (NASDAQ:INOD) market cap rose US$76m last week but retail investors profited the most

Ezcorp (EZPW) Flat As Market Gains: What You Should Know

Zacks

10 months ago

Ezcorp (EZPW) Flat As Market Gains: What You Should Know

Financial Statement Series: Fisker Stock Analysis

Motley Fool

10 months ago

Financial Statement Series: Fisker Stock Analysis

Gritstone bio (NASDAQ:GRTS) investors are sitting on a loss of 87% if they invested three years ago

Simply Wall St.

10 months ago

Gritstone bio (NASDAQ:GRTS) investors are sitting on a loss of 87% if they invested three years ago

MasterCraft Boat Holdings, Inc. to Webcast Fiscal Second Quarter 2024 Earnings Conference Call Wednesday, February 7, 2024

GlobeNewswire

10 months ago

MasterCraft Boat Holdings, Inc. to Webcast Fiscal Second Quarter 2024 Earnings Conference Call Wednesday, February 7, 2024

Gilead Sciences, Citi, Digital World Acquisition: Top Stocks

Yahoo Finance Video

10 months ago

Gilead Sciences, Citi, Digital World Acquisition: Top Stocks

Trump-linked stocks soar after DeSantis throws in the towel

Reuters

10 months ago

Trump-linked stocks soar after DeSantis throws in the towel

Consensus Cloud Solutions to Host Q4 and 2023 Year End Investor Call on February 21, 2024

Business Wire

10 months ago

Consensus Cloud Solutions to Host Q4 and 2023 Year End Investor Call on February 21, 2024

W&T Offshore Announces Closing of Accretive Acquisition of Six Gulf of Mexico Fields

GlobeNewswire

10 months ago

W&T Offshore Announces Closing of Accretive Acquisition of Six Gulf of Mexico Fields

3 Things to Know About Dutch Bros Stock

Motley Fool

10 months ago

3 Things to Know About Dutch Bros Stock

The past year for Arrow Financial (NASDAQ:AROW) investors has not been profitable

Simply Wall St.

10 months ago

The past year for Arrow Financial (NASDAQ:AROW) investors has not been profitable

Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long

Simply Wall St.

10 months ago

Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

10 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Funko and Goliath Announce Exclusive Global Deal for Funko Games

Business Wire

10 months ago

Funko and Goliath Announce Exclusive Global Deal for Funko Games

Cantaloupe, Inc. to Report Second Quarter Fiscal Year 2024 Results on February 8, 2024

Business Wire

10 months ago

Cantaloupe, Inc. to Report Second Quarter Fiscal Year 2024 Results on February 8, 2024

Calculating The Fair Value Of Vishay Precision Group, Inc. (NYSE:VPG)

Simply Wall St.

10 months ago

Calculating The Fair Value Of Vishay Precision Group, Inc. (NYSE:VPG)

Julie Andrews Begins as New Chief Financial Officer at Orthofix

Business Wire

10 months ago

Julie Andrews Begins as New Chief Financial Officer at Orthofix

Groupon (GRPN) Is Attractively Priced Despite Fast-paced Momentum

Zacks

10 months ago

Groupon (GRPN) Is Attractively Priced Despite Fast-paced Momentum

Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

Zacks

10 months ago

Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Zacks

10 months ago

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Stagwell (STGW) and MNTN Partner to Forge a Unified Performance Marketing Ecosystem for Brands

PR Newswire

10 months ago

Stagwell (STGW) and MNTN Partner to Forge a Unified Performance Marketing Ecosystem for Brands

VNET Welcomes New Executive Director to Board

PR Newswire

10 months ago

VNET Welcomes New Executive Director to Board

Here's Why We Think Esquire Financial Holdings (NASDAQ:ESQ) Might Deserve Your Attention Today

Simply Wall St.

10 months ago

Here's Why We Think Esquire Financial Holdings (NASDAQ:ESQ) Might Deserve Your Attention Today

Xponential (XPOF) Posts Robust 2023 Operating Highlights

Zacks

10 months ago

Xponential (XPOF) Posts Robust 2023 Operating Highlights

3 Stocks Set to Soar 68% to 200% Higher

InvestorPlace

10 months ago

3 Stocks Set to Soar 68% to 200% Higher

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

Business Wire

10 months ago

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

Gannett to Present at the 26th Annual Needham Growth Conference

Business Wire

10 months ago

Gannett to Present at the 26th Annual Needham Growth Conference

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

10 months ago

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Guaranty Bancshares, Inc. Announces Fourth Quarter and Year-End 2023 Earnings Release and Conference Call Schedule

Business Wire

10 months ago

Guaranty Bancshares, Inc. Announces Fourth Quarter and Year-End 2023 Earnings Release and Conference Call Schedule

The Best-Performing REITs Of 2023

Benzinga

10 months ago

The Best-Performing REITs Of 2023

Financial Institutions, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

GlobeNewswire

10 months ago

Financial Institutions, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Medifast's (MED) Holistic Health Solution, Innovation Bode Well

Zacks

a year ago

Medifast's (MED) Holistic Health Solution, Innovation Bode Well

Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?

Motley Fool

a year ago

Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?

Allspring Closed-End Funds Adopt Amended and Restated By-Laws

PR Newswire

a year ago

Allspring Closed-End Funds Adopt Amended and Restated By-Laws

Great Lakes Dredge & Dock Co. Announces Significant Status Update on its Maritime Administration (“MARAD”) Title XI Financing Application

GlobeNewswire

a year ago

Great Lakes Dredge & Dock Co. Announces Significant Status Update on its Maritime Administration (“MARAD”) Title XI Financing Application

VersaBank donates $50,000 to Salvation Army to support Harvest Hope food security campaign

CNW Group

a year ago

VersaBank donates $50,000 to Salvation Army to support Harvest Hope food security campaign

Shareholders in Funko (NASDAQ:FNKO) are in the red if they invested five years ago

Simply Wall St.

a year ago

Shareholders in Funko (NASDAQ:FNKO) are in the red if they invested five years ago

Guaranty Bancshares, Inc. Declares Quarterly Cash Dividend

Business Wire

a year ago

Guaranty Bancshares, Inc. Declares Quarterly Cash Dividend

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

Zacks

a year ago

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

Investors still aren’t sold on UniQure’s gene therapy for Huntington’s

BioPharma Dive

a year ago

Investors still aren’t sold on UniQure’s gene therapy for Huntington’s

7 Stocks with Strong Insider Buying: December 2023

InvestorPlace

a year ago

7 Stocks with Strong Insider Buying: December 2023

First Bancorp Announces Cash Dividend

PR Newswire

a year ago

First Bancorp Announces Cash Dividend

Share on Social Networks: